The BT-Reveal Early Pancreatic Cancer Test is intended for use as a screening tool for at-risk individuals. A positive result does not guarantee the individual has cancer. For all positive results, additional follow-up imaging and other confirmatory tests are recommended. Common follow up testing includes CT Scans, MRI’s, Endoscopic Ultrasounds, or ERCP tests.

Breakthrough Genomics’s clinical laboratory in Irvine, California is certified in the U.S. under the Clinical Laboratory Improvements Amendments (CLIA) and by the College of American Pathologists (CAP) to perform high complexity clinical genomic tests. The BT-Reveal Early Pancreatic Cancer Test only requires a 10ml tube of blood that can be stored and transported at room temperature. The test is currently being offered as a Laboratory Developed Test (LDT) and as such surpasses the lab’s requirements needed to be able to safely provide the test to at-risk individuals.